Stockscreener 앱 받기
0.9099
5.44%
-0.0523
전일 마감가:
$0.9622
열려 있는:
$0.9652
하루 거래량:
455.01K
Relative Volume:
0.26
시가총액:
$5.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.88
$0.99
1주일 범위
$0.7622
$1.41
52주 변동 폭
$0.7622
$1.41
Decoy Therapeutics Inc Stock (DCOY) Company Profile
명칭
Decoy Therapeutics Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
DCOY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
0.9099 | 6.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
DCOY Stock Price, News & Analysis - Stock Titan
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
DCOY SEC FilingsDECOY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - TipRanks
DCOYDecoy Therapeutics Inc Stock Price and Quote - Finviz
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Australia
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Canada
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewswire
Salarius Pharma (NASDAQ: SLRX) notes CapIQ errors, has ~$14M cash post Decoy merger - Stock Titan
Salarius Pharmaceuticals clarifies continued Nasdaq listing after merger - Investing.com
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger - citybiz
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger - TechStock²
Salarius Pharmaceuticals, Inc. (SLRX) Stock: Plunges 51% After $7M Public Offering Announcement - parameter.io
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - Stock Titan
Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion - Investing.com
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO - Investing.com
Salarius Pharmaceuticals announces 1-for-15 reverse stock split - marketscreener.com
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
Salarius Pharmaceuticals granted Nasdaq extension to regain listing compliance - Investing.com
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - Yahoo Finance
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com
Salarius Pharmaceuticals Faces Financial Struggles Amid Merger Deal and Delisting Threats - StockInvest.us
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com
SLRXSalarius Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Bo - GuruFocus
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - marketscreener.com
Valerio Therapeutics announces acquisition of Emglev Therapeutics - Pharmaceutical Technology
Salarius: Q2 Earnings Snapshot - marketscreener.com
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting - marketscreener.com
Decoy Therapeutics Inc (DCOY) 재무 분석
Decoy Therapeutics Inc (DCOY)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Decoy Therapeutics Inc 주식 (DCOY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
4.73%
0.92%
자본화:
|
볼륨(24시간):